Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Matinas BioPharma sees Q2 adjusted EBITDA $4M-$6M » 06:35
05/12/22
05/12
06:35
05/12/22
06:35
MTNB

Matinas BioPharma

/

+

Sees Q2 ex-TAC gross…

Sees Q2 ex-TAC gross profit $59M-$62M.

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
MTNB Matinas BioPharma
/

+

Hot Stocks
Matinas BioPharma sees FY22 adjusted EBITDA $50M-$60M » 06:34
05/12/22
05/12
06:34
05/12/22
06:34
MTNB

Matinas BioPharma

/

+

Sees FY22 ex-TAC gross…

Sees FY22 ex-TAC gross profit $270M-$290M.

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
MTNB Matinas BioPharma
/

+

Earnings
Matinas BioPharma reports Q1 adjusted EPS 0c, consensus 0c » 06:33
05/12/22
05/12
06:33
05/12/22
06:33
MTNB

Matinas BioPharma

/

+

Reports Q1 revenue…

Reports Q1 revenue $254.2M, consensus $242.24M. "We met our Ex TAC gross profit guidance and exceeded our profitability guidance for the first quarter," said co-CEO David Kostman. "We are lowering our full year 2022 guidance and increasing the size of our range to reflect the demand softness we see, particularly in Europe, and general economic uncertainty. We believe that our strong momentum of publisher partner wins and market share gains in Q1, in addition to our investments in technology and product will position us well for the future. We have a strong balance sheet and are committed to balancing growth and profitability." "We remain focused on product innovation, quality, and building trust and transparency with our partners," added Yaron Galai, Outbrain's Co-Founder and Co-CEO. "As you will hear on our conference call, I am very excited to announce the next step in our evolution with the launch of Keystone, our total business optimization platform for media owners."

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
MTNB Matinas BioPharma
/

+

Over a month ago
Recommendations
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab » 11:03
04/11/22
04/11
11:03
04/11/22
11:03
MTNB

Matinas BioPharma

/

+

, BNTX

BioNTech

$167.05 /

-3.14 (-1.84%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein notes Matinas Biopharma (MTNB) announced it has entered into a collaboration agreement with BioNTech (BNTX), aimed at exploring novel delivery routes for mRNA vaccines. The analyst believes that as mRNA vaccines have taken center stage in recent years, the next evolutionary step as a modality aims to increase ease of delivery by development of a bioavailable oral solution. The news reinforces his thesis as he views the current LNC collaboration opportunities as a sample of prospective applications for the platform, which can provide future upside. Fein has a Buy rating and a price target of $3 on Matinas' shares.

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

BNTX BioNTech
$167.05 /

-3.14 (-1.84%)

MTNB Matinas BioPharma
/

+

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
BNTX BioNTech
$167.05 /

-3.14 (-1.84%)

04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
02/01/22 Redburn
BioNTech upgraded to Neutral from Sell at Redburn
01/19/22 Credit Suisse
Genmab price target lowered to DKK 2,600 from DKK 2,850 at Credit Suisse
MTNB Matinas BioPharma
/

+

BNTX BioNTech
$167.05 /

-3.14 (-1.84%)

BNTX BioNTech
$167.05 /

-3.14 (-1.84%)

BNTX BioNTech
$167.05 /

-3.14 (-1.84%)

BNTX BioNTech
$167.05 /

-3.14 (-1.84%)

Hot Stocks
BioNTech, Matinas enter research collaboration for mRNA-based vaccines » 07:08
04/11/22
04/11
07:08
04/11/22
07:08
BNTX

BioNTech

$170.19 /

+1.21 (+0.72%)

, MTNB

Matinas BioPharma

$0.78 /

+0.0069 (+0.90%)

BioNTech SE (BNTX) and…

BioNTech SE (BNTX) and Matinas BioPharma (MTNB) announced that they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. The parties will closely collaborate on formulation, optimization, and in vitro testing. Under the terms of the agreement, Matinas will receive an upfront access fee to work exclusively with BioNTech, as well as additional research funding from BioNTech. The parties have also commenced discussions on a license agreement for Matinas' LNC platform technology.

ShowHide Related Items >><<
MTNB Matinas BioPharma
$0.78 /

+0.0069 (+0.90%)

BNTX BioNTech
$170.19 /

+1.21 (+0.72%)

BNTX BioNTech
$170.19 /

+1.21 (+0.72%)

04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
02/01/22 Redburn
BioNTech upgraded to Neutral from Sell at Redburn
01/19/22 Credit Suisse
Genmab price target lowered to DKK 2,600 from DKK 2,850 at Credit Suisse
MTNB Matinas BioPharma
$0.78 /

+0.0069 (+0.90%)

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
MTNB Matinas BioPharma
$0.78 /

+0.0069 (+0.90%)

BNTX BioNTech
$170.19 /

+1.21 (+0.72%)

BNTX BioNTech
$170.19 /

+1.21 (+0.72%)

BNTX BioNTech
$170.19 /

+1.21 (+0.72%)

BNTX BioNTech
$170.19 /

+1.21 (+0.72%)

Earnings
Matinas BioPharma reports Q4 EPS (3c), consensus (3c) » 06:32
03/08/22
03/08
06:32
03/08/22
06:32
MTNB

Matinas BioPharma

/

+

Reports Q4 revenue $0,…

Reports Q4 revenue $0, consensus $470,000. Cash, cash equivalents and marketable securities at December 31, 2021, were approximately $49.6M, compared to $58.7M at December 31, 2020. Based on current projections, the Company believes that cash on hand is sufficient to fund planned operations through 2023. "We are proud of the significant progress we made in 2021 to advance our LNC platform technology, including delivering compelling data for MAT2203 in the first three cohorts of the EnACT trial and meeting with the FDA for an End of Phase 2 meeting," commented Jerome D. Jabbour, CEO. "In 2022, in addition to delivering data from Cohort 4 of the EnACT trial in the third quarter, we have moved aggressively into the formulation and delivery of nucleic acids and have initiated internal discovery programs based on the delivery of mRNA, DNA and antisense oligonucleotides. While we are very excited about our infectious disease small molecule programs, we believe that our LNC delivery technology has the potential to become a preferred and novel modality for the targeted intracellular delivery of these complex therapeutics. The unique properties of our LNC platform, including oral bioavailability, extrahepatic targeting, large payload capacity, and improved stability and safety, are supported by key preclinical data that differentiates our technology from both lipid nanoparticles and viral vectors. We believe these unique properties represent the next generation in intracellular drug delivery."

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
03/30/21 H.C. Wainwright
Matinas BioPharma price target lowered to $3 from $4 at H.C. Wainwright
MTNB Matinas BioPharma
/

+

Over a quarter ago
Hot Stocks
Matinas BioPharma provides update on its ongoing programs » 06:48
01/25/22
01/25
06:48
01/25/22
06:48
MTNB

Matinas BioPharma

/

+

Matinas BioPharma…

Matinas BioPharma Holdings is providing a business update on each of its ongoing programs. "We made tremendous progress in 2021, completely transitioning our Company and significantly advancing our LNC platform technology," commented Jerome D. Jabbour, CEO. "Despite the resurgence of COVID-19 with both Delta and Omicron variants, our team was able to deliver compelling data for MAT2203 in the first three cohorts of the EnACT trial, which then facilitated an important and highly productive End of Phase 2 meeting with the FDA in December of 2021. Based upon FDA's support and feedback, we are preparing to expand the EnACT trial to provide additional confirmatory data in support of MAT2203 as step-down therapy for induction treatment, which we believe could position us to submit a New Drug Application in late 2023." The company provided updates on MAT2203 Program; LNC Platform Collaborations; MAT2501 Program; and LYPDISO Program.

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
03/30/21 H.C. Wainwright
Matinas BioPharma price target lowered to $3 from $4 at H.C. Wainwright
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
MTNB Matinas BioPharma
/

+

Hot Stocks
Matinas BioPharma reports $49.9M in cash and equivalents at end of FY21 » 06:40
01/25/22
01/25
06:40
01/25/22
06:40
MTNB

Matinas BioPharma

/

+

The Company's…

The Company's preliminary, unaudited estimate of cash, cash equivalents and marketable securities at December 31, 2021, is approximately $49.9M, subject to completion of the audit of the Company's consolidated financial statements for the year ended December 31, 2021. This compares to $58.7M at December 31, 2020. Based on current projections, the Company believes that cash on hand is sufficient to fund planned operations through 2023.

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
03/30/21 H.C. Wainwright
Matinas BioPharma price target lowered to $3 from $4 at H.C. Wainwright
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
MTNB Matinas BioPharma
/

+

Conference/Events
Matinas BioPharma to host business news update conference call » 08:25
01/24/22
01/24
08:25
01/24/22
08:25
MTNB

Matinas BioPharma

/

+

Management holds a…

Management holds a business news update conference call on January 25 at 8:30 am. Webcast Link

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
03/30/21 H.C. Wainwright
Matinas BioPharma price target lowered to $3 from $4 at H.C. Wainwright
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
MTNB Matinas BioPharma
/

+

Conference/Events
Matinas BioPharma to host business news update conference call » 04:55
01/24/22
01/24
04:55
01/24/22
04:55
MTNB

Matinas BioPharma

/

+

Management holds a…

Management holds a business news update conference call on January 25 at 8:30 am. Webcast Link

ShowHide Related Items >><<
MTNB Matinas BioPharma
/

+

MTNB Matinas BioPharma
/

+

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
03/30/21 H.C. Wainwright
Matinas BioPharma price target lowered to $3 from $4 at H.C. Wainwright
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler
MTNB Matinas BioPharma
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.